Published in Medical Letter on the CDC and FDA, March 7th, 2004
That compares with sales of $11.7 million reported in the fourth quarter a year ago.
For the full year 2003, global net sales of Campath recorded by ILEX's marketing and distribution partner, Schering, AG, Germany (SHR) and its U.S. affiliate Berlex Laboratories, totaled $71.7 million, compared to $44.1 million in 2002.
"We were pleased to see our product-focused strategy pay off in 2003," said ILEX President and CEO Jeff Buchalter. "The growth outlook for Campath continues to be quite...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.